"a technology toreliably deliver 7D10 into cells has not previously been identified. Patrys and itscollaborators and Yale University have shown that PAT-DX1 is targeted to tumors and can enter and kill cancer cells."
Most drugs can only attach themselves to cancer cells but are only mildly effective , patrys have the technology to enter and kill cancer cells.
PAB valuation should be much higher imo on this technology alone. The partnering and licencing potential is enormous.
Ann: Collaboration with WEHI, page-2
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $3.875K | 553.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 3120846 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1568171 | 2 |
View Market Depth
| Last trade - 13.18pm 05/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |